Congo Ebola Outbreak: Merck Ervebo Vaccine, Gilead Remdesivir Eyed for Wider Use

Merck & Co.'s Ervebo vaccine and Gilead Sciences' Remdesivir antiviral drug will be deployed for wider use in eastern Democratic Republic of Congo. This deployment aims to control the fastest-growing Ebola outbreak recorded to date.